Loading…
← CockpitCompetitor Analysis › HRMY Harmony Biosciences Holdings, Inc.Open in the cockpit ↗

Harmony Biosciences Holdings, Inc.HRMYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Rare-disease specialty pharma selling Wakix for narcolepsy and building a broader sleep-disorder pipeline.

Momentum neutral 41
Mkt cap
$1.94B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$41.4M
20-day average traded
Fwd P/E
8.6×
forward earnings
ROIC−WACC
+22.8 pp
WACC 9.6%
Hurdle
-51 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$33.11
1D+0.3%
1W-3.2%
1M-14.4%
3M-13.0%
6M+5.5%
YTD-11.5%
1Y-2.6%
ATR %4.4%
Beta0.63
52w lowhigh23.9% off high

What Harmony Biosciences does

Rare-disease specialty pharma selling Wakix for narcolepsy and building a broader sleep-disorder pipeline.

Nearly all revenue comes from Wakix, sold through a small number of specialty pharmacies to patients whose doctors prescribe it, and reported net of rebates and discounts. Pitolisant came through a licence from Bioprojet, a French drug developer, to which royalties are paid.

Products and services

  • Wakix (narcolepsy)
  • Pipeline (idiopathic hypersomnia, other rare disease)

Customers

  • Sleep-medicine specialists
  • Neurologists

Where it sits in the supply chain

  • Rare-disease pharmaceuticals
  • Narcolepsy/sleep-disorder drug…
  • Specialty sales force

What could go right

  • Wakix volume/label growth
  • New rare-disease pipeline additions

What could go wrong

  • Single-product revenue concentration
  • Payer/reimbursement pressure on rare-disease pricing

Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and a first-in-class mechanism protect Wakix from direct generic competition.

Headquarters: Plymouth Meeting, Pennsylvania, US · Founded: 2017 · Employees: 293

Named competitors

Harmony Biosciences at a glance

Size Harmony Biosciences (HRMY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.94B, the 1790th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.11 on 18 Nov 2026.

Performance Over six months the shares gained 5.5%, against -5.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 19.8% over the last twelve months (peer median +8.7%); the operating margin is 22.2% (peer median 17.9%).

Valuation It trades at 8.6× forward earnings against a peer median of 22.8× (cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -51 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 22.8 points above its cost of capital (9.6% WACC).

Short interest Short interest is 11.3% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026HRMY 109Peer median 93
Six months, rebased to 100: Harmony Biosciences against the median of its 20 peers (local-currency closes).

Harmony Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$989M$868M$715M$582M$438M
Revenue growth—+22%+23%+33%—
Gross profit$709M$646M$534M$437M$331M
EBITDA$245M$234M$215M$216M$144M
Net income$179M$159M$145M$129M$181M
Free cash flow$323M$348M$219M$219M$144M
Capital expenditure$19.4M$19.6M$27.7M$312,000$40.2M
Total debt$233M$235M$233M$196M$193M

Quarterly statements and history in the cockpit →

Harmony Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%ONESOURCEBHVN60020145400512SHILPAMEDERISALIVUS9969009420PFIZER300009600211300436COHANCE603456603707600285000908DMPHRMY6-month return →1-month return →
Up and to the right = strong over both horizons. Harmony Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×ONESOURCE60020145400512SHILPAMEDERISALIVUS9969PFIZER300009COHANCE603707DMPHRMYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Harmony Biosciences is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%60020105129969PFIZER600285HRMYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Harmony Biosciences is the large dot.

Harmony Biosciences competitors and peer comparison

Head to head with its named competitors (HRMY vs JAZZ vs 4502.T vs AXSM)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Harmony Biosciences HRMY$1.94B+6%+20%22%8.6×-10.5%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Axsome Therapeutics AXSM$7.05B-42%+54%-19%77.1×n/a
Alkermes Public ALKS$7.87B+27%+15%5%n/a32.5%

How Harmony Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Harmony Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureHRMYPeer medianRank in peer set
1-month return-14.4%+2.7%2nd lowest of 21
6-month return+5.5%-5.5%9th highest of 21
Distance from 52-week high-23.9%-28.8%9th highest of 21
Revenue growth (TTM)+19.8%+8.7%4th highest of 20
Operating margin22.2%17.9%8th highest of 20
Forward P/E8.6×22.8×cheapest of 17
Growth the price implies (Req g, 7 yrs)-10.5%3.4%least demanding of 13
Growth delivered (Del g)+40.3%+9.9%2nd highest of 13
Hurdle (Req g minus delivered)-50.8 pp-6.3 pp2nd least demanding of 13
ROIC minus cost of capital+22.8 pp+0.1 pp3rd highest of 20
EV / EBITDA5.7×17.8×cheapest of 10
Net debt / EBITDA-2.2×1.4×2nd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%

Questions

Who are Harmony Biosciences's main competitors?
Named competitors: Jazz Pharmaceuticals (JAZZ), Avadel Pharmaceuticals (private or unlisted), Takeda (4502.T), Axsome Therapeutics (AXSM), Alkermes (ALKS), Centessa Pharmaceuticals (private or unlisted). The cockpit's measured peer set (industry) also includes OneSource Specialty Pharma (ONESOURCE.NS), Biohaven (BHVN), Jinyu Bio-Technology (600201.SS), Tsumura & (4540.T), Grand Pharmaceutical (0512.HK), Shilpa Medicare (SHILPAMED.NS).
Is Harmony Biosciences expensive compared with its peers?
On forward p/e it trades at 8.6× against a peer median of 22.8×, cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -51 pp: the price already allows for a slowdown.
How has Harmony Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +5.5% against -5.5% for the median peer; over one year -2.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.